VICT2 Trait: Prognostic Alternative to Peritumoral Hepatobiliary Phase Hypointensity in HCC

被引:33
作者
Jiang, Hanyu [1 ]
Wei, Hong [1 ]
Yang, Ting [1 ]
Qin, Yun [1 ]
Wu, Yuanan [3 ]
Chen, Weixia [1 ]
Shi, Yujun [2 ]
Ronot, Maxime [4 ,5 ]
Bashir, Mustafa R. [6 ,7 ]
Song, Bin [1 ,8 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Radiol, NHC, 37 Guoxue Alley, Chengdu 610041, Peoples R China
[2] Sichuan Univ, West China Hosp, Lab Pathol, Key Lab Transplant Engn & Immunol,NHS, 37 Guoxue Alley, Chengdu 610041, Peoples R China
[3] Univ Elect Sci & Technol China, Big Data Res Ctr, Chengdu, Peoples R China
[4] Univ Paris Cite, UMR 1149, CRI, Paris, France
[5] Hop Beaujon, APHP Nord, Serv Radiol, Clichy, France
[6] Duke Univ, Ctr Adv Magnet Resonance Med, Dept Radiol, Med Ctr, Durham, NC USA
[7] Duke Univ, Dept Med, Div Gastroenterol, Med Ctr, Durham, NC USA
[8] Sanya Peoples Hosp, Dept Radiol, Sanya, Peoples R China
基金
中国国家自然科学基金;
关键词
ACID-ENHANCED MRI; MICROVASCULAR INVASION; HEPATOCELLULAR-CARCINOMA; GADOXETIC ACID; EXPRESSION; PREDICTION; DIAGNOSIS; OUTCOMES; OATP1B3; CANCER;
D O I
10.1148/radiol.221835
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Peritumoral hepatobiliary phase (HBP) hypointensity is an established prognostic imaging feature in hepatocellular car-cinoma (HCC), often associated with microvascular invasion (MVI). Similar prognostic features are needed for non-HBP MRI. Purpose: To propose a non-hepatobiliary-specific MRI tool with similar prognostic value to peritumoral HBP hypointensity.Materials and Methods: From December 2011 to November 2021, consecutive patients with HCC who underwent preoperative con-trast-enhanced MRI were retrospectively enrolled and followed up until recurrence. All MRI scans were reviewed by two blinded radiologists with 7 and 10 years of experiences with liver MRI. A scoring system based on non-hepatobiliary-specific features that highly correlated with peritumoral HBP hypointensity was identified in a stratified sampling-derived training set of the gadoxetate disodium (EOB) group by means of multivariable logistic regression, and its values to predict MVI and recurrence-free survival (RFS) were assessed.Results: There were 660 patients (551 men; median age, 53 years; IQR, 45-61 years) enrolled. Peritumoral portal venous phase hypoenhancement (odds ratio [OR] = 8.8), incomplete "capsule" (OR = 3.3), corona enhancement (OR, 2.6), and peritumoral mild-moderate T2 hyperintensity (OR, 2.2) (all P < .001) were associated with peritumoral HBP hypointensity and constituted the "VICT2 trait" (test set area under the receiver operating characteristic curve = 0.84; 95% CI: 0.78, 0.90). For the EOB group, both peritumoral HBP hypointensity (OR for MVI = 2.5, P = .02; hazard ratio for RFS = 2.5, P < .001) and the VICT2 trait (OR for MVI = 5.1, P < .001; hazard ratio for RFS = 2.3, P < .001) were associated with MVI and RFS, despite a higher specificity of the VICT2 trait for MVI (89% vs 80%, P = .01). These values of the VICT2 trait were confirmed in the extracellular contrast agent group (OR for MVI = 4.0; hazard ratio for RFS = 1.7; both P < .001).Conclusion: Based on four non-hepatobiliary-specific MRI features, the VICT2 trait was comparable to peritumoral hepatobiliary phase hypointensity in predicting microvascular invasion and postoperative recurrence of hepatocellular carcinoma.
引用
收藏
页数:11
相关论文
共 36 条
[1]  
[Anonymous], CT/MRI Liver Imaging Reporting and Data System version 2018
[2]   Hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with HCC: prognostic features before resection, ablation, or TACE [J].
Bae, Jae Seok ;
Kim, Jung Hoon ;
Lee, Dong Ho ;
Kim, Jae Hyun ;
Han, Joon Koo .
EUROPEAN RADIOLOGY, 2021, 31 (06) :3627-3637
[3]   A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma [J].
Banerjee, Sudeep ;
Wang, David S. ;
Kim, Hyun J. ;
Sirlin, Claude B. ;
Chan, Michael G. ;
Korn, Ronald L. ;
Rutman, Aaron M. ;
Siripongsakun, Surachate ;
Lu, David ;
Imanbayev, Galym ;
Kuo, Michael D. .
HEPATOLOGY, 2015, 62 (03) :792-800
[4]   Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD [J].
Bastati, Nina ;
Beer, Lucian ;
Ba-Ssalamah, Ahmed ;
Poetter-Lang, Sarah ;
Ambros, Raphael ;
Kristic, Antonia ;
Lauber, David ;
Pomej, Katharina ;
Binter, Teresa ;
Simbrunner, Benedikt ;
Semmler, Georg ;
Balcar, Lorenz ;
Bican, Yesim ;
Hodge, Jacqueline C. ;
Wrba, Thomas ;
Trauner, Michael ;
Reiberger, Thomas ;
Mandorfer, Mattias .
JOURNAL OF HEPATOLOGY, 2022, 77 (04) :1005-1013
[5]   Prediction of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma using imaging features of gadoxetic acid-enhanced magnetic resonance imaging [J].
Byun, Jieun ;
Kim, So Yeon ;
Kim, Jin Hyoung ;
Kim, Min Ju ;
Yoo, Changhoon ;
Shim, Ju Hyun ;
Lee, Seung Soo .
ACTA RADIOLOGICA, 2021, 62 (12) :1548-1558
[6]   LI-RADS Version 2018 Ancillary Features at MRI [J].
Cerny, Milena ;
Chernyak, Victoria ;
Olivie, Damien ;
Billiard, Jean-Sebastien ;
Murphy-Lavallee, Jessica ;
Kielar, Ania Z. ;
Elsayes, Khaled M. ;
Bourque, Laurence ;
Hooker, Jonathan C. ;
Sirlin, Claude B. ;
Tang, An .
RADIOGRAPHICS, 2018, 38 (07) :1973-2001
[7]  
Collins GS, 2015, J CLIN EPIDEMIOL, V68, P112, DOI [10.7326/M14-0697, 10.7326/M14-0698, 10.1002/bjs.9736, 10.1016/j.eururo.2014.11.025, 10.1111/eci.12376, 10.1186/s12916-014-0241-z, 10.1016/j.jclinepi.2014.11.010, 10.1136/bmj.g7594, 10.1038/bjc.2014.639]
[8]  
Commission GOoNH, 2022, J. Clin. Hepatol, V38, P306
[9]   Tumour evolution in hepatocellular carcinoma [J].
Craig, Amanda J. ;
Von Felden, Johann ;
Garcia-Lezana, Teresa ;
Sarcognato, Samantha ;
Villanueva, Augusto .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (03) :139-152
[10]   Microvascular invasion of small hepatocellular carcinoma can be preoperatively predicted by the 3D quantification of MRI [J].
Dong, San-Yuan ;
Wang, Wen-Tao ;
Chen, Xiao-Shan ;
Yang, Yu-Tao ;
Zhu, Shuo ;
Zeng, Meng-Su ;
Rao, Sheng-Xiang .
EUROPEAN RADIOLOGY, 2022, 32 (06) :4198-4209